匹伐他汀、阿托伐他汀和瑞舒伐他汀安全性及疗效的随机头对头比较（低密度脂蛋白的量与质）：——PATROL试验 - Suppr | 超能文献

[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].

作者信息

Saku Keijiro, Zhang Bo, Noda Keita

机构信息

Department of Cardiology, Fukuoka University School of Medicine, Japan.

出版信息

Nihon Naika Gakkai Zasshi. 2011 Dec 10;100(12):3679-86. doi: 10.2169/naika.100.3679.

DOI:10.2169/naika.100.3679

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].匹伐他汀、阿托伐他汀和瑞舒伐他汀安全性及疗效的随机头对头比较（低密度脂蛋白的量与质）：——PATROL试验

Nihon Naika Gakkai Zasshi. 2011 Dec 10;100(12):3679-86. doi: 10.2169/naika.100.3679.

2

Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.随机头对头比较匹伐他汀、阿托伐他汀和瑞舒伐他汀的安全性和疗效（LDL 的数量和质量）：PATROL 试验。

Circ J. 2011;75(6):1493-505. doi: 10.1253/circj.cj-10-1281. Epub 2011 Apr 15.

3

Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?强效他汀类药物作为高危患者血脂异常的主要治疗药物：它们是否都一样？

Circ J. 2011;75(6):1326-7. doi: 10.1253/circj.cj-11-0410. Epub 2011 Apr 29.

4

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.瑞舒伐他汀10毫克/天与阿托伐他汀10毫克/天对高危成年人影响的12周多中心随机开放标签比较：一项探索性研究

Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015.

5

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).瑞舒伐他汀与阿托伐他汀对南亚冠心病高危患者的比较（来自IRIS试验）

Am J Cardiol. 2007 Jun 1;99(11):1538-43. doi: 10.1016/j.amjcard.2007.01.028. Epub 2007 Apr 16.

6

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.瑞舒伐他汀与阿托伐他汀利弊比较：来自头对头随机对照试验的荟萃分析

Am J Cardiol. 2008 Dec 15;102(12):1654-62. doi: 10.1016/j.amjcard.2008.08.014. Epub 2008 Sep 20.

7

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.瑞舒伐他汀与阿托伐他汀治疗高胆固醇血症合并冠心病高危患者的疗效及安全性：一项随机对照试验

Am Heart J. 2004 Jul;148(1):e4. doi: 10.1016/j.ahj.2004.01.020.

8

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).瑞舒伐他汀与阿托伐他汀、辛伐他汀和普伐他汀不同剂量疗效及安全性的比较（STELLAR*试验）

Am J Cardiol. 2003 Jul 15;92(2):152-60. doi: 10.1016/s0002-9149(03)00530-7.

9

More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.与阿托伐他汀、普伐他汀或辛伐他汀治疗相比，更多西方高胆固醇血症患者使用瑞舒伐他汀治疗可达到日本动脉粥样硬化协会的低密度脂蛋白胆固醇（LDL-C）目标。

Circ J. 2004 Feb;68(2):107-13. doi: 10.1253/circj.68.107.

10

Is rosuvastatin really a more efficient therapeutic option than atorvastatin?瑞舒伐他汀真的是比阿托伐他汀更有效的治疗选择吗？

Value Health. 2006 Jul-Aug;9(4):276-7; author reply 277-9. doi: 10.1111/j.1524-4733.2006.00111.x.

引用本文的文献

1

Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.比较 7 种他汀类药物在血脂异常、心血管疾病或糖尿病患者中的降脂/增脂疗效：50 项随机对照试验的系统评价和网络荟萃分析。

Cardiovasc Ther. 2020 Apr 23;2020:3987065. doi: 10.1155/2020/3987065. eCollection 2020.